Infanrix–polio+hib

Haemophilus influenzae type b conjugate vaccine; Inactivated poliovirus vaccine, the active ingredient in Infanrix–polio+hib, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity against Haemophilus influenzae type b and poliovirus, protecting infants and young children from Hib disease and poliomyelitis.

GNH USA supplies Infanrix–polio+hib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable cold‑chain logistics and regulatory support to ensure product integrity across global markets. Clients benefit from timely delivery, comprehensive documentation, and dedicated technical assistance.

Infanrix–polio+hib is used in pediatric immunization programs to protect against bacterial and viral pathogens. - Haemophilus influenzae type b infection: provides active immunity that prevents invasive Hib disease such as meningitis and pneumonia in infants. - Poliomyelitis: induces protective antibodies against poliovirus types 1, 2 and 3, reducing risk of paralytic polio. - Routine childhood vaccination schedule: administered as part of the combined DTP‑Hib‑IPV series to simplify immunization visits.

Following intramuscular administration, Infanrix–polio+hib may be associated with local and systemic reactions.

Common Side Effects: - Pain at injection site: mild to moderate discomfort lasting a few hours to a day. - Redness and swelling: localized erythema and edema that typically resolve within 2‑3 days. - Fever: low‑grade temperature rise (≤38.5 °C) occurring within 24‑48 hours after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with hives, breathing difficulty, and hypotension that requires immediate medical attention. - Seizures: febrile or non‑febrile convulsions reported rarely, especially in infants with high fever. - Guillain‑Barré syndrome: extremely rare autoimmune neuropathy presenting with muscle weakness and tingling.

Healthcare providers should consider the following precautions when administering Infanrix–polio+hib. - Contraindication: severe allergic reaction to any vaccine component or previous dose. - Caution: postpone vaccination in children with moderate or severe acute illness. - Immunocompromised patients: vaccine may be less immunogenic; assess risk‑benefit. - Fever monitoring: observe for high fever after injection and treat symptomatically. - Co‑administration: simultaneous receipt of live vaccines may affect immune response; follow schedule guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix–polio+hib has limited documented drug interactions, but the following should be noted.

Major Interactions (Avoid): - None identified: no major drug interactions have been reported with this vaccine. - Immunoglobulin therapy: concurrent administration may reduce antibody response to the vaccine antigens.

Moderate Interactions (Monitor Closely): - Antipyretic prophylaxis: routine use of acetaminophen or ibuprofen before vaccination may blunt immunogenicity. - Corticosteroids: systemic steroids may diminish the vaccine‑induced immune response. - Other vaccines: simultaneous administration may increase the frequency of local reactions.